Eli Lilly Stock

Thinking about investing in the pharmaceutical sector? Take a look at major industry player Eli Lilly. Read on for a comprehensive guide to the company.

You have no doubt heard of the notorious antidepressant Prozac, which has been around since the 1980s. The american pharmaceutical company Eli Lilly discovered and patented the drug, that some refer to as “happy pills”.

Eli Lilly is one of the largest pharmaceutical groups in the world. In 2020, the company achieved a turnover of 21.91 billion euros. 

With its research and innovation-driven business model, Eli Lilly attracts a lot of interest from investors. Read on for more information on the company's stock. 

History of Eli Lilly

Eli Lilly and Company is an American pharmaceutical company based in Indianapolis. It was founded in 1876 by Colonel Eli Lilly, a chemist-pharmacist and veteran of the American Civil War. 

Eli Lilly has made history in pharmaceutical research since its inception and continues to make its mark today. It was the first company to mass-produce the polio vaccine and human insulin. Today, it is the leading manufacturer of psychiatric drugs. 

Here are a few important dates in the history of the group : 

  • 1923 : Two researchers from JJR Macleod and Frederick Banting won the Nobel Prize for their research on insulin. 
  • 1952 : the company's shares were opened to the public. 
  • 1980s : Acquisition of Physio-Control Corporation and Advance Cardiovascular Systems.
  • 1990s : acquisition of Pacific Biotech and PCS Systems.
  • 2017 : acquisition of CoLucid Pharmaceuticals. 
  • 2018 : acquisition of Armo Biosciences.  
  • 2018 : IPO of Elanco Animal Health, the company's veterinary products arm. 
  • 2019 : acquisition of Loxo Oncology. 
  • 2020 : acquisition of Dermira.  

Eli Lilly and Company's business lines

Eli Lilly is engaged in the research, development, production and distribution of pharmaceutical products for human health. It also produces veterinary products for animal health. 

In March 2021, Eli Lilly employed 34,689 people, 19,258 of whom were located outside the United States. The group has subsidiaries all over the world, in France, India, China, Sweden, Vietnam, Pakistan, Japan, Philippines, Germany, Lithuania and Venezuela among others. It comprises some twenty companies, including Valquifarma, ImClone Systems, Spaly Bioquimica, AurKa Pharma.  

Here’s a breakdown of the companies’ revenue by activity : 

  • Endocrinology (mainly diabetes treatment) : 47.6 %
  • Oncology (cancer treatment) : 17.4 %
  • Veterinary medicine : 12.8 %
  • Treatment of cardiovascular disease : 9.2 %
  • Neurology : 7.4 %
  • Treatment of immune diseases : 4.6 %
  • Other activities : 1 %

Eli Lilly Group stock market data : 

  • Year of IPO : 1952
  • Isin code : US5324571083
  • Share price as of April 30, 2021 : $182.77 

Factors in favour of Eli Lilly Group stock 

It should be noted that the treatment of diabetes provides the company with almost half of its annual turnover. The number of people with diabetes worldwide is currently 463 million, a figure that may increase by a third within 20 years. And that's without taking into account the fact that one out of every two patients is undiagnosed. All this means that drugs will be needed for decades to come. 

The Eli Lilly group is also strengthening its presence in cancer treatment with the acquisition of ImClone and Loxo Oncology. Its anti-cancer drug Alimta generates more than $2 billion in sales. It also has other drugs such as Cyramza, to which it holds exclusive patent rights. 

Eli Lilly is an innovative company. Its greatest strength lies in its investment in research and development, alongside its strong international presence. 

Factors that may cause Eli Lilly Group's share prices to fall 

Eli Lilly was criminally convicted in 2009 for illegally marketing its antipsychotic drug Zyprexa. The company was forced to pay $1.41 billion in a case that tarnishes its image to this day.